A class action lawsuit has been filed in federal court against the Indian drug manufacturer Ranbaxy after it recalled its generic version of Lipitor when it was discovered to contain glass fragments. Small glass particles at least 1 mm in size may pose a risk for consumers. Parts of a missing glass shield at the company’s India facility are suspected of being the source of the fragments. Due to manufacturing problems, Ranbaxy is only allowed to sell generic Lipitor in the United States after the FDA banned about 30 of its drugs from the market in this country. Ranbaxy is also accused of faking data sent to the FDA. The federal lawsuit alleges that Ranbaxy has not done enough to warn consumers about the dangers of the glass fragments in the recalled Lipitor equivalent. It also seeks a refund and damages payments for anyone who got the recalled drug, fines that would prevent Ranbaxy from profiting from the recalled products, an injunction against future sales of Ranbaxy generic atorvastin and punitive damages.